The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.
 
Neal Shiv Chawla
No Relationships to Disclose
 
Ted Kim
No Relationships to Disclose
 
Travis Sherman
No Relationships to Disclose
 
Jonathan Dang
No Relationships to Disclose
 
Victoria S. Chua
No Relationships to Disclose
 
Ania Moradkhani
No Relationships to Disclose
 
Ishrat Bhuiyan
No Relationships to Disclose
 
Nathalie Krkyan
No Relationships to Disclose
 
Mitchel Fernando
No Relationships to Disclose
 
Emma Colletti
No Relationships to Disclose
 
William Feske
No Relationships to Disclose
 
Kitty Zheng
No Relationships to Disclose
 
Warren Allen Chow
Consulting or Advisory Role - GlaxoSmithKline
Speakers' Bureau - Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline
Other Relationship - Advenchen Laboratories; Via Oncology
 
Mark Agulnik
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Lilly; Regeneron
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Deciphera
Research Funding - Exelixis (Inst)
 
Doris Quon
No Relationships to Disclose
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Erlinda Maria Gordon
No Relationships to Disclose
 
Arun S. Singh
Stock and Other Ownership Interests - AntiCancer; Certis Oncology Solutions
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Lilly
Speakers' Bureau - Daiichi Sankyo; Deciphera; Eisai; Lilly; MJH Life Sciences; Novartis; Scripps Health
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); deciphera (Inst); Lilly (Inst); Nanocarrier (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; Eisai; Lilly; Novartis
Other Relationship - Certis Oncology Solutions